FOXP3+促炎性T细胞:克罗恩病的潜在治疗靶点
本研究对克罗恩病患者回肠活检分离的CD4+ T细胞进行单细胞RNA测序并与健康对照比较,鉴定出5个FOXP3+调节性T细胞亚群,其中促炎性亚群对肿瘤坏死因子-α信号有独特反应且体外抑制功能受损。组蛋白去乙酰化酶抑制剂伏立诺他可在体外恢复正常基因表达模式并挽救FOXP3+细胞的抑制功能。
要点
- 在克罗恩病患者中鉴定出新的促炎性FOXP3+ T细胞亚群。
- 该亚群体外抑制活性受损,对肿瘤坏死因子-α信号有独特反应。
- 伏立诺他在体外可挽救FOXP3+细胞的抑制功能。
核心结论
- 在克罗恩病患者中鉴定出新的促炎性FOXP3+ T细胞亚群,并建立用美国食品药品监督管理局批准的药物伏立诺他靶向这些细胞的流程。
研究设计与样本
- 对克罗恩病患者与健康个体回肠活检分离的CD4+ T细胞进行单细胞RNA测序,行聚类分析和基因信号网络分析,并将差异表达基因与公开微阵列数据集重叠,进一步行体外抑制实验和类器官系统功能研究。
主要发现
- 鉴定出5个不同的FOXP3+调节性T细胞亚群,来自健康对照的调节性T细胞代表向炎症相关亚型假时序发育的起点。
- 促炎性调节性T细胞对肿瘤坏死因子-α信号显示独特反应性,体外抑制活性受损,在类器官共培养系统中细胞因子反应升高。
- 如计算机模拟预测,组蛋白去乙酰化酶抑制剂伏立诺他使基因表达模式正常化,在体外挽救FOXP3+细胞的抑制功能。
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND & AIMS: The incidence of Crohn's disease (CD) continues to increase worldwide. The contribution of CD4+ cell populations remains to be elucidated. We aimed to provide an in-depth transcriptional assessment of CD4+ T cells driving chronic inflammation in CD. METHODS: We performed single-cell RNA-sequencing in CD4+ T cells isolated from ileal biopsies of patients with CD compared with healthy individuals. Cells underwent clustering analysis, followed by analysis of gene signaling networks. We overlapped our differentially expressed genes with publicly available microarray data sets and performed functional in vitro studies, including an in vitro suppression assay and organoid systems, to model gene expression changes observed in CD regulatory T (Treg) cells and to test predicted therapeutics. RESULTS: We identified 5 distinct FOXP3+ regulatory Treg subpopulations. Tregs isolated from healthy controls represent the origin of pseudotemporal development into inflammation-associated subtypes. These proinflammatory Tregs displayed a unique responsiveness to tumor necrosis factor-α signaling with impaired suppressive activity in vitro and an elevated cytokine response in an organoid coculture system. As predicted in silico, the histone deacetylase inhibitor vorinostat normalized gene expression patterns, rescuing the suppressive function of FOXP3+ cells in vitro. CONCLUSIONS: We identified a novel, proinflammatory FOXP3+ T cell subpopulation in patients with CD and developed a pipeline to specifically target these cells using the US Food and Drug Administration-approved drug vorinostat.
引用
- Kosinsky RL, Gonzalez MM, Saul D, et al. The FOXP3+ Pro-Inflammatory T Cell: A Potential Therapeutic Target in Crohn's Disease. Gastroenterology. 2024. PMID: 38211712. doi:10.1053/j.gastro.2024.01.007
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。